Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82553 | 1.00 | F10 (0.33) | F10GRIN2BHPGDPTK2GRM5 | |
| SCHEMBL86801 | 0.89 | F10 (0.33) | F10GRIN2BHPGDPTK2HDAC8 | |
| SCHEMBL86703 | 0.83 | PIK3CB (0.35) | F10GRIN2BHPGDPTK2GRM5 | |
| SCHEMBL82551 | 0.82 | THRB (0.33) | F10RXFP1RAB9ANPC1KDM4E | |
| SCHEMBL82525 | 0.82 | THRB (0.33) | F10RXFP1RAB9ANPC1KDM4E | |
| SCHEMBL86681 | 0.81 | ADORA3 (0.32) | F10GRIN2BPTK2GRM5 | |
| SCHEMBL87151 | 0.81 | PIK3CB (0.38) | F10GRIN2BPTK2GRM5RAB9A | |
| SCHEMBL87168 | 0.80 | GRIN2B (0.34) | F10GRIN2BPTK2GRM5ALDH1A1 | |
| SCHEMBL86624 | 0.79 | PTAFR (0.34) | HDAC8RAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL82216 | 0.79 | FGFR3 (0.34) | F10GRIN2BRXFP1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | claimed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | claimed |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | BAYER CONSUMER CARE AG (CH) | 2021-11-30 | — | — | US | disclosed |
| EP-3843743-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | Bayer AS (NO) | 2021-07-07 | — | — | EP | disclosed |
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2021-06-24 | — | — | US | disclosed |
| US-10925880-B2 | Combination of PI3K-inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| WO-2020164997-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-20 | — | — | WO | disclosed |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | BAYER CONSUMER CARE AG (CH) | 2020-07-16 | — | — | US | disclosed |
| WO-2020043617-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | BAYER AS (NO) | 2020-03-05 | — | — | WO | disclosed |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-22 | — | — | US | disclosed |
| US-10383877-B2 | Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-08-20 | — | — | US | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187134-A1 | COMBINATION OF PI3K-INHIBITORS AND TARGETED THORIUM CONJUGATES | PIK3CA, PIK3CD, PIK3CB | F10 3761/4885GRIN2B 2816/4885HPGD 4285/4885 |
| US-11185549-B2 | Combination of a PI3K-inhibitor with an androgen receptor antagonist | AR, PIK3CA, AKT3 | F10 3443/4885GRIN2B 1044/4885HPGD 1986/4885 |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | F10 2878/4885GRIN2B 1519/4885HPGD 1618/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | F10 2527/4885GRIN2B 2834/4885HPGD 735/4885 |
| US-10383877-B2 | Use of substituted 2, 3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | MCL1, BCL9, BCL3 | F10 2391/4885GRIN2B 4778/4885HPGD 609/4885 |
| US-10925880-B2 | Combination of PI3K-inhibitors | BCL9L, BCL9, MALT1 | F10 1946/4885GRIN2B 3356/4885HPGD 4599/4885 |
| US-20190255063-A1 | COMBINATION OF PI3K-INHIBITORS | BCL9L, BCL9, MALT1 | F10 1946/4885GRIN2B 3356/4885HPGD 4599/4885 |
| US-20200222414-A1 | COMBINATION OF A PI3K-INHIBITOR WITH AN ANDROGEN RECEPTOR ANTAGONIST | AR, GSK3B, PIK3CA | F10 4543/4885GRIN2B 735/4885HPGD 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.